Oncology

The FDA staff report questioned the unusually poor performance of the control group used in the study.

Newly diagnosed multiple myeloma patients undergoing ASCT showed a significant improvement in survival.

The US FDA has warned that intravenous administration docetaxal formulations contain alcohol and may cause intoxication among patients. A product label revision is being made.

Ira Klein, MD, MBA, FACP, chief medical officer, National Accounts Clinical Sales & Strategy, Aetna, suggests that oncology practices lack a sense of economic perspective that would otherwise allow them to offer a variety of services to their patients.

A panel asks: "Due to the ACA, who is now presenting with cancer? Who is walking through the door and is there a difference between patients since the ACA implementation?"

From 20 months to upto 5 years, blocking CD20 significantly improved OS in CLL patients.

For patients who survive cancer, annual medical costs can be nearly double those of non-cancer patients.

Twenty-two Democratic lawmakers have asked the National Institutes of Health to publicly disclose demographic data for all clinical trials posted on ClinicalTrials.gov.

The derivative slowed tumor growth, shrunk tumors, and extended the life of the mice.

BRCA2 mutation, a genetic risk factor for breast and ovarian cancer, has been implicated in squamous cell lung cancer among cigarette smokers.

Pfizer's deal with the French company will ensure a market share in the promising immunooncology field.

The oncolytic adenovirus vaccine, DNX-2401, being developed by DNAtrix to treat recurrent glioblastoma, has received a fast-track status by the FDA.

In community-based radiology practice, mammography screening with 3D digital breast tomosynthesis (DBT) yielded lower recall rates, an increased overall cancer detection rate, and an increased detection rate for invasive cancer compared with 2D digital mammography (DM).

Icahn School of Medicine at Mount Sinai and Champions Oncology have initiated a study evaluating TumorGrafts' ability to predict treatment benefit in patients with triple-negative breast cancer. A side-by-side genomic analysis of patients' tumor and TumorGraft mouse avatars, before and after treatment, will also be conducted.

Low-dose dexamethasone with pomalidomide improved overall survival to 12.7 months, compared to 5.7 months with high-dose dexamethasone.

A bold new way to test cancer drugs started Monday in hundreds of hospitals around the United States.

A proteomic test can predict outcome with chemotherapy versus erlotinib in NSCLC patients.

The FDA has approved the diagnostic agent technetium 99m tilmanocept for the detection of the spread of head and neck cancers.

Cutting edge technology used to image young children with heart disease increases their risk of cancer.

Ventana Medical Systems, Inc. and MedImmune today announced they are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune's MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma. This includes the recently commenced MEDI4736 ATLANTIC trial that will enroll only patients who express PD-L1 as determined by the VENTANA assay.

New research suggests that a reduction in blood cholesterol might actually prove harmful in kidney cancer patients.

CYRAMZAâ„¢ (ramucirumab)did not meet its primary endpoint; overall survival favored the CYRAMZA arm but was not statistically significant, in patients with hepatocellular carcinoma, but meaningful improvements in key secondary endpoints of progression-free survival, overall response rate and time to progression were observed.

Pembrolizumab was safe and effective in patients with locally advanced or metastatic non—small cell lung cancer that strongly expressed PD-L1, according to study results presented at the ASCO Annual Meeting.